Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oxidative polymorphism of debrisoquine is not related to the risk of Alzheimer's disease.

Journal of the neurological sciences - 1 Jul 1993

Benítez J, Barquero M S, Coria F, Molina J A, Jiménez-Jiménez F J, Ladero J M

Abstract excerpt

Oxidative polymorphism of debrisoquine has been studied in patients suffering from many spontaneous disorders which show genetic and/or environmental factors in their pathogenesis. To elucidate whether any relationship exists between this genetic polymorphism and the risk of developing Alzheimer disease (AD) we determined the oxidative phenotype and metabolic ratio (MR) of debrisoquine (DBQ) in 47 patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Alzheimer Disease
Share to Cytochrome P-450 Enzyme System

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Oxidation-Reduction

Share to Phenotype

Share to Polymorphism, Genetic

Share to Risk Factors

Source

Identifiers

PMID: 8410072
DOI: 10.1016/0022-510x(93)90146-p

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oxidative polymorphism of debrisoquine is not related to the risk of Alzheimer's disease.PMID 8410072Read ↗

Pharmacogenetics of Debrisoquine and its Use as a Marker For CYP2D6 Hydroxylation CapacitySemantic proximity Read ↗

Debrisoquine oxidation in an Italian population: a study in healthy subjects and in schizophrenic patients.Semantic proximity Read ↗

Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in a large population.Semantic proximity Read ↗

Debrisoquine oxidation polymorphism in patients with chronic inflammatory bowel disease.Semantic proximity Read ↗

Debrisoquine metabolism in Chinese patients with Alzheimer's and Parkinson's diseases.Semantic proximity Read ↗

Evidence for the polymorphic oxidation of debrisoquine in the Thai population.Semantic proximity Read ↗

Clinical consequences of polymorphic drug oxidation.Semantic proximity Read ↗

Polymorphic debrisoquin metabolism in a Turkish population.Semantic proximity Read ↗

Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease.Semantic proximity Read ↗

Genetically determined adverse drug reactions involving metabolism.Semantic proximity Read ↗

Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects.Semantic proximity Read ↗

Oxidation phenotyping with debrisoquine in Germany (East).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.